How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,845 results for

Tongue Carcinoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1681. Mucosal neuroma syndrome--a phenotype for malignancy. (PubMed)

Mucosal neuroma syndrome--a phenotype for malignancy. The mucosal neuroma syndrome is characterised by a typical physical appearance, neuromata on tongue and buccal mucosa, and a high risk of developing medullary thyroid carcinoma and phaeochromocytoma. A case is described and the importance of early recognition for prevention of malignancy is stressed.

Full Text available with Trip Pro

1985 Archives of Disease in Childhood

1682. An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay. (PubMed)

An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay. The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34 patients with other types of lung cancer and 35 patients with benign diseases. To compare the results with those obtained by the conventional competitive radioimmunoassay (RIA) using a polyclonal (...) higher with the IRMA method than with the RIA method in SCC of all organs, as much as 2-3 times higher in SCC of the larynx, tongue and pharynx. In contrast, in patients with benign diseases or other types of lung cancer, there was no difference in the positive ratios between the two methods. This was largely due to the improvement in sensitivity and accuracy of assay with the new method, which resulted in a decrease in the normal value in healthy controls. It was concluded that with the new IRMA

Full Text available with Trip Pro

1990 British journal of cancer

1683. Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Carcinoma of the Oropharynx Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Untreated Metastatic Squamous Neck Cancer With Occult Primary Drug: erlotinib hydrochloride Drug: docetaxel Radiation: radiation therapy Procedure: therapeutic conventional surgery Other: laboratory biomarker analysis Other: pharmacological study Phase 1 Detailed Description: PRIMARY OBJECTIVES: I. Determine MTD and toxicity of combination of EGFR inhibitor (OSI-774 (...) , Verrucous Nasopharyngeal Carcinoma Neoplasms, Unknown Primary Tongue Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms by Site Respiratory Tract Diseases Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Respiratory Tract Neoplasms Pharyngeal Neoplasms Pharyngeal Diseases Stomatognathic Diseases Nasopharyngeal Neoplasms Nasopharyngeal Diseases Neoplasm Metastasis Neoplastic Processes Pathologic Processes Mouth Neoplasms

2002 Clinical Trials

1684. Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with radiation therapy with or without cisplatin may kill more tumor cells. Condition or disease Intervention/treatment Phase Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity Stage II Squamous Cell Carcinoma of the Oropharynx Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Stage III Squamous Cell Carcinoma of the Oropharynx Stage (...) IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Oropharynx Drug: erlotinib hydrochloride Drug: cisplatin Radiation: intensity-modulated radiation therapy Other: laboratory biomarker analysis Phase 1 Detailed Description: PRIMARY OBJECTIVES: I. Determination of the maximally tolerated dose (MTD) of the combination of daily oral OSI-774 and standard fractionation external beam radiation therapy in patients with oral cavity (OC) or oropharyngeal (OP

2002 Clinical Trials

1685. Phase II Trial of Allovectin-7® for Head and Neck Cancer

, Pennsylvania, United States, 19104 Sponsors and Collaborators Vical More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00028457 Other Study ID Numbers: VCL-1005-207 First Posted: December 9, 2002 Last Update Posted: June 24, 2008 Last Verified: June 2008 Keywords provided by Vical: Cancer Carcinoma Neoplasm Head cancer Neck cancer Tongue cancer Lip cancer Oral Cavity Oropharynx Pharynx Larynx Squamous Cell Salivary Glands Tumor Lesion (...) is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression. Condition or disease Intervention/treatment Phase Head and Neck Cancer Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Head and Neck Neoplasms Carcinoma of the Head and Neck Genetic: Allovectin-7® Phase 3 Detailed Description: Treatment - If you take part

2002 Clinical Trials

1686. Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

Verified: February 2011 Keywords provided by National Cancer Institute (NCI): stage II squamous cell carcinoma of the lip and oral cavity stage III squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the lip and oral cavity stage II squamous cell carcinoma of the oropharynx stage III squamous cell carcinoma of the oropharynx stage IV squamous cell carcinoma of the oropharynx tongue cancer Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Squamous (...) surgery Procedure: neoadjuvant therapy Radiation: radiation therapy Phase 3 Detailed Description: OBJECTIVES: Compare the disease-free and overall survival in patients with previously untreated squamous cell carcinoma of the oral cavity or oropharynx treated with resection with or without and neoadjuvant and adjuvant perilymphatic interleukin-2 (IL-2) and radiotherapy. Compare the response rate in patients treated with these regimens. Determine the local and systemic effects of locoregional IL-2

1999 Clinical Trials

1687. Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer

: Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate) Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy Patients upstaged by imaging to N2 are eligible Measurable or evaluable disease Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies No distant metastases PATIENT (...) CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No active untreated infection No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin No concurrent major medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: More than 3 months since prior chemotherapy

2000 Clinical Trials

1688. Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

tablets commencing 3 days prior to irradiation Drug: pilocarpine hydrochloride 5mg pilocarpine hydrochloride tablets Placebo Comparator: Placebo Placebo tablets commencing 3 days prior to irradiation Other: Placebo Outcome Measures Go to Primary Outcome Measures : Acute salivary gland toxicity [ Time Frame: From the start of treatment to 13 weeks ] Secondary Outcome Measures : Acute mucositis in the pharynx, palate, tongue, or buccal [ Time Frame: From the start of treatment to 13 weeks ] Quality (...) to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 120 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically proven oral cavity and/or oropharyngeal squamous cell carcinoma Radiation volume to encompass at least 50% of parotid

1999 Clinical Trials

1689. Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer

for Study: 18 Years to 120 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV (T2-T4) squamous cell carcinoma of the larynx or oropharynx No recurrent disease No evidence of distant metastasis Resectable disease, defined as follows: High probability of attaining clear surgical margins (for disease of the base of tongue, tonsil, soft palate, or pharyngeal wall) No extension to root of tongue (...) preservation rate in patients with stage III or IV squamous cell carcinoma of the larynx or oropharynx treated with paclitaxel and carboplatin followed by paclitaxel with concurrent radiotherapy. Determine the feasibility and toxicity of this regimen in these patients. Determine the utility of pre- and post-treatment organ function instruments on swallowing ability and voice quality in patients treated with this regimen. Determine the disease-free survival and patterns of failure of patients treated

2001 Clinical Trials

1690. Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx

therapy Radiation: low-LET electron therapy Radiation: low-LET photon therapy Phase 3 Detailed Description: OBJECTIVES: I. Compare, in a phase III setting, overall and disease-free survival with preservation of laryngeal function in patients with stage III/IV squamous cell carcinoma of the glottic and supraglottic larynx treated with cisplatin/fluorouracil (CDDP/5-FU) followed by radiotherapy vs. concomitant radiotherapy plus CDDP vs. radiotherapy alone. II. Compare the tumor response after completion (...) about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Biopsy-proven, previously untreated, squamous cell carcinoma of the glottic and supraglottic larynx that would normally require total laryngectomy Stage III/IV disease

1999 Clinical Trials

1691. Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Drug: ixabepilone Other: laboratory biomarker analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To determine the response rate and toxicity of BMS-247550 given in two dosing schedules in taxane-naïve and taxane-exposed patients. II. To provide information about the response (...) Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent

2002 Clinical Trials

1692. The Effects of Upper Airway and Digestive Tract Tumors on the Immune System

(NIDCD) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage. Previous studies have shown that tumors of the vocal tract produce signals that could help the tumor escape the body's immune defenses and use the body's energy and mineral stores to grow (...) . Researchers are hoping to learn more about what signals give tumor cells an advantage to live and grow, how tumor cells control these signals, and how these signals affect the rest of the body. This study will look closer at researchers belief that tumors in the vocal tract contain genes (genetic information) that abnormally function to allow the tumors to survive and grow against the attack of the body's normal immune system Patients with cancerous tumors (squamous cell carcinoma) and benign (non

1999 Clinical Trials

1693. Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer

and systemic paclitaxel and carboplatin in patients with recurrent squamous cell carcinoma of the head and neck. II. Determine the safety of this regimen in this patient population. III. Determine the time to progression, pattern of progression, and rate of relapse of patients treated with this regimen. VI. Determine the time to response and duration of response of patients treated with this regimen. V. Determine the overall survival of patients treated with this regimen. OUTLINE: This is a multicenter (...) Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse Study Start Date : November 2000 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important

2001 Clinical Trials

1694. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Ages Eligible for Study: 15 Years to 80 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed squamous cell or poorly differentiated carcinomas, or lymphoepithelioma of the head and neck Stage III carcinoma of the base of the tongue or hypopharynx Stage IV carcinoma of the oral cavity, pharynx (including nasopharynx, oropharynx, and hypopharynx), or larynx No distant metastasis (...) carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the oropharynx stage IV lymphoepithelioma of the oropharynx stage IV squamous cell carcinoma of the nasopharynx stage IV lymphoepithelioma of the nasopharynx stage III squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the larynx Additional relevant MeSH terms: Layout table for MeSH terms Head

1999 Clinical Trials

1695. A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer

Neoplasm Squamous Cell Carcinoma Drug: paclitaxel concurrent with radiation therapy Phase 1 Detailed Description: This is a pilot study designed to evaluate the toxicity of a five day infusion of Paclitaxel concurrent with radiation therapy for advanced head and neck cancers. Patients with previously untreated Stage III and IV squamous cell cancer (SCC) of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx and maxillary sinus, as well as Stage II SCC of the base of the tongue, nasopharynx (...) for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria INCLUSION CRITERIA Patients must satisfy the following criteria: The patient must have a biopsy proven diagnosis of carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, maxillary sinus. Squamous cell, lymphoepithelioma, transitional cell and undifferentiated histologies will be included. We will accept AJCC stages III-IV for all the sites

1999 Clinical Trials

1696. Clinical report on the L95P mutation in a Dutch family with paraganglioma. (PubMed)

at the age of 34 years, a T4 planocellular carcinoma of the tongue occurred within the previous radiation field 27 years later, when the patient was 61 years old. Volume measurements of three untreated glomus tumors (two glomus vagale tumors, one glomus caroticum tumor) during 25 months showed an increase in two tumors (left glomus caroticum, left glomus vagale tumor) and a decrease in one tumor (right glomus vagale tumor). Surgery to remove two bilateral and one unilateral glomus caroticum tumors (...) was successful. A wait-and-see policy is being applied to two glomus vagale tumors.In family members of paraganglioma 1 patients, mutation analysis can be used to make an early diagnosis of glomus tumors. Radiotherapy may have induced a carcinoma. Modalities of treatment can include a wait-and-see policy. Long-term follow-up studies on the natural course of glomus tumors are needed to improve decisions about treatment modalities.

2002 Otology and Neurotology

1697. Erosive pustular dermatosis of the leg: report of three cases. (PubMed)

for erosive pustular dermatosis. The lesions rapidly responded to topical treatment with either tacrolimus or corticosteroids. Of note, this condition was associated with a diverticular disease in two patients, while in another patient an epidermoid carcinoma of the tongue was present. Erosive pustular dermatosis of the leg is an uncommon but distinct skin disorder typically associated with trophic changes of the lower limbs. Our observations raise the question of the relation of erosive pustular

2002 British Journal of Dermatology

1698. [Risk factors of late complications after interstitial 192Ir brachytherapy in cancers of the oral cavity]. (PubMed)

[Risk factors of late complications after interstitial 192Ir brachytherapy in cancers of the oral cavity]. Brachytherapy has confirmed its prevailing role in conservative treatment of oral cavity carcinomas. To describe late toxicity in long-term surviving patients, comparisons with other series are necessary. Study of series of patients implanted for floor of the mouth or mobile tongue shows the need for more detailed data. Dental prophylaxy and lead protection of the mandibule, good

1998 Cancer radiothérapie : journal de la Société française de radiothérapie oncologique

1699. Oculocutaneous manifestations in xeroderma pigmentosa. (PubMed)

Oculocutaneous manifestations in xeroderma pigmentosa. Xeroderma pigmentosum (XP) is a rare genetic disease characterised by defective DNA repair leading to clinical and cellular hypersensitivity to ultraviolet radiation. The oculocutaneous features of 10 patients with XP were studied retrospectively. General features included parental consanguinity (40%), familiarity (60%), onset of symptoms in first 2 years (50%), malignant skin neoplasms (60%), and carcinoma of the tongue (20%). Among (...) the ocular features, 50% of patients presented with photophobia. Lid freckles or atrophic skin lesions were seen in all patients. Lower lid tumours were seen in 30%, chronic conjunctival congestion in 40%, corneal opacification in 40%, squamous cell carcinoma of limbus in 20%, bilateral pterygium in 40%, and visual impairment in 50%. The clinical features (ocular and cutaneous) of the cases are discussed.

Full Text available with Trip Pro

1994 The British journal of ophthalmology

1700. Oral cancer (PubMed)

Oral cancer 11342519 2001 08 30 2018 11 13 0093-0415 174 5 2001 May The Western journal of medicine West. J. Med. Oral cancer. 348-51 Scully C C Eastman Dental Institute for Oral Health Care Sciences, University College London, University of London, 256, Gray's Inn Road, London, WC1X 8LD, UK. c.scully@eastman.ucl.ac.uk Porter S S eng Journal Article United States West J Med 0410504 0093-0415 AIM IM Biopsy, Needle Carcinoma, Squamous Cell diagnosis mortality therapy Combined Modality Therapy (...) Female Humans Lip Neoplasms diagnosis therapy Male Mouth Neoplasms diagnosis mortality therapy Prognosis Radiotherapy methods Surgical Procedures, Operative methods Survival Rate Tongue Neoplasms diagnosis therapy 2001 5 9 10 0 2001 8 31 10 1 2001 5 9 10 0 ppublish 11342519 PMC1071397 Oral Dis. 1999 Jul;5(3):206-9 10483065 J Am Dent Assoc. 1999 Oct;130(10):1445-57 10570588 J Craniomaxillofac Surg. 1999 Jun;27(3):187-91 10442311 Br J Oral Maxillofac Surg. 1999 Jun;37(3):164-74 10454022 Crit Rev Oncol

Full Text available with Trip Pro

2001 Western Journal of Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>